000			01853 am a22002533u 4500
042			_adc
100	1	0	_aDu, Ping _eauthor _9796
700	1	0	_aJung, Jeah _eauthor _9797
700	1	0	_aKalidindi, Yamini _eauthor _9798
700	1	0	_aFarrow, Kevin _eauthor _9799
700	1	0	_aRiley, Thomas _eauthor _9800
700	1	0	_aWhitener, Cynthia _eauthor _9801
245	0	0	_aLow utilization of direct-acting antiviral agents in a large national cohort of HIV and HCV co-infected Medicare patients in the United States: Implications for HCV elimination
260			_c2022.
500			_a/pmc/articles/PMC7391052/
500			_a/pubmed/32011599
520			_aHCV infection is common in people living with HIV/AIDS (PLWHA). The advent of direct-acting antiviral agents (DAAs) has made HCV elimination a realistic goal. We conducted a retrospective cohort study using the U.S. Medicare Fee-For-Service claims data and outpatient prescription drug data to assess the HCV DAA initiation and completion among newly diagnosed HIV-HCV co-infected Medicare patients enrolled in 2014-2016. DAA initiation was defined as filling at least one prescription of DAAs during 2014-2016. DAA completion was defined as taking an 8-week or longer DAA treatment course for patients without cirrhosis and a 12-week or longer treatment duration for those with cirrhosis. Among 12,152 HIV-HCV co-infected Medicare patients, 20.9% received the DAA treatment in 2014-2016. The average time from HCV diagnosis to DAA initiation was 277 days. The overall DAA completion rate was 92% among 2,537 patients who used DAAs. Interventions are needed to improve DAA uptake in PLWHA.
540			_a
546			_aen
690			_aArticle
655	7		_aText _2local
786	0		_nJ Public Health Manag Pract
856	4	1	_uhttp://dx.doi.org/10.1097/PHH.0000000000001147 _zConnect to this object online.
999			_c1362 _d1362